Home Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease
Article
Licensed
Unlicensed Requires Authentication

Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease

  • Oliviero Olivieri EMAIL logo , Carmela Chiariello , Nicola Martinelli , Annalisa Castagna , Giulia Speziali , Domenico Girelli , Francesca Pizzolo , Antonella Bassi , Daniela Cecconi , Elisa Robotti , Marcello Manfredi , Eleonora Conte and Emilio Marengo
Published/Copyright: April 13, 2018
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 56 Issue 9

Abstract

Background:

Apolipoprotein C-III (ApoC-III), a key regulator of plasma triglyceride (TG), is present in three isoforms, i.e. non-sialylated (ApoC-III0), monosialylated (ApoC-III1) and disialylated (ApoC-III2). We aimed at quantifying the distribution of the ApoC-III glycoforms in patients with angiographically demonstrated coronary artery disease (CAD) according to levels of total ApoC-III plasma concentration.

Methods:

ApoC-III glycoforms were quantified by a specifically developed, high-resolution, mass spectrometry method in unrelated CAD patients. Lipoprotein lipase (LPL) activity was estimated by a fluorescence-based method.

Results:

In 101 statin-treated CAD patients, the absolute concentrations of the three glycoforms similarly increased across ApoC-III quartiles, but the proportion of ApoC-III1 rose whereas that of ApoC-III0 decreased progressively by increasing total ApoC-III concentrations. The proportion of ApoC-III2 was quite constant throughout the whole range of total ApoC-III. A higher proportion of ApoC-III1 reflected an unfavorable lipid profile characterized by high levels of TG, total and low density lipoprotein cholesterol, ApoE and reduced ApoA-I. The correlations between ApoC-III glycoforms and TG were confirmed in 50 statin-free CAD patients. High concentration of total ApoC-III was associated with low LPL activity, while no correlation was found for the relative proportion of glycoforms.

Conclusions:

Specific patterns of ApoC-III glycoforms are present across different total ApoC-III concentrations in CAD patients. The inhibitory effect of ApoC-III on LPL appears related to total ApoC-III concentration, but not to the relative proportion of ApoC-III glycoforms.

Keywords: apolipoprotein C-III; coronary artery disease; glycoforms; lipoprotein lipase; plasma lipids
Corresponding author: Oliviero Olivieri, Professor of Internal Medicine, Department of Medicine, Unit of Internal Medicine, University of Verona, Policlinico G.B. Rossi, Piazzale Antonio Scuro 1, 37134 Verona, Italy
aCurrent address: Azienda Socio Sanitaria di Mantova Strada Lago Paiolo, n. 10, Mantova, Italy.

Acknowledgments

The work was performed in part in the LURM (Laboratorio Universitario di Ricerca Medica) Research Center, University of Verona.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: OO and NM acknowledge the support of Fondazione CariVerona (B36J16002570003, Funder id: 10.13039/501100006747). MM acknowledges the support of Fondazione CRT project Lagrange.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Zhao T, Zhao J. Association of the apolipoprotein A5 gene -1131 T>C polymorphism with fasting blood lipids: a meta-analysis in 37859 subjects. BMC Med Genet 2010;11:120.10.1186/1471-2350-11-120Search in Google Scholar PubMed PubMed Central

2. Laurila PP, Naukkarinen J, Kristiansson K, Ripatti S, Kauttu T, Silander K, et al. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:346–52.10.1161/ATVBAHA.109.188912Search in Google Scholar PubMed PubMed Central

3. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371:22–31.10.1056/NEJMoa1307095Search in Google Scholar PubMed PubMed Central

4. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985;26:556–65.10.1016/S0022-2275(20)34342-XSearch in Google Scholar

5. Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010;121:1722–34.10.1161/CIRCULATIONAHA.109.875807Search in Google Scholar PubMed PubMed Central

6. Olivieri O, Martinelli N, Baroni M, Branchini A, Girelli D, Friso S, et al. Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele. J Am Heart Assoc 2013;2:e000440.10.1161/JAHA.113.000440Search in Google Scholar PubMed PubMed Central

7. Nicolardi S, van der Burgt YE, Dragan I, Hensbergen PJ, Deelder AM. Identification of new apolipoprotein-CIII glycoforms with ultrahigh resolution MALDI-FTICR mass spectrometry of human sera. J Proteome Res 2013;12:2260–8.10.1021/pr400136pSearch in Google Scholar PubMed

8. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972;46:375–82.10.1016/S0006-291X(72)80149-9Search in Google Scholar

9. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985;75:384–90.10.1172/JCI111711Search in Google Scholar PubMed PubMed Central

10. Yamamoto M, Morita SY, Kumon M, Kawabe M, Nishitsuji K, Saito H, et al. Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions. Biochim Biophys Acta 2003;1632:31–9.10.1016/S1388-1981(03)00058-1Search in Google Scholar PubMed

11. Li Y, He PP, Zhang DW, Zheng XL, Cayabyab FS, Yin WD, et al. Lipoprotein lipase: from gene to atherosclerosis. Atherosclerosis 2014;237:597–608.10.1016/j.atherosclerosis.2014.10.016Search in Google Scholar PubMed

12. Olivieri O, Martinelli N, Girelli D, Pizzolo F, Friso S, Beltrame F, et al. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. J Thromb Haemost 2010;8:463–71.10.1111/j.1538-7836.2009.03720.xSearch in Google Scholar PubMed

13. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 2003;44:2374–81.10.1194/jlr.M300253-JLR200Search in Google Scholar PubMed

14. Jian W, Edom RW, Wang D, Weng N, Zhang SW. Relative quantitation of glycoisoforms of intact apolipoprotein C3 in human plasma by liquid chromatography-high-resolution mass spectrometry. Anal Chem 2013;85:2867–74.10.1021/ac3034757Search in Google Scholar PubMed

15. Cvijetic S, Bortolotto V, Manfredi M, Ranzato E, Marengo E, Salem R, et al. Cell autonomous and noncell-autonomous role of NF-κB p50 in astrocyte-mediated fate specification of adult neural progenitor cells. GLIA 2017;65:169–81.10.1002/glia.23085Search in Google Scholar PubMed

16. Dalle Carbonare L, Manfredi M, Caviglia G, Conte E, Robotti E, Marengo E. et al. Can half-marathon affect overall health? The yin-yang of sport. J Proteomics 2018;170:80–7.10.1016/j.jprot.2017.09.004Search in Google Scholar PubMed

17. Yassine HN, Trenchevska O, Ramrakhiani A, Parekh A, Koska J, Walker RW, et al. The association of human apolipoprotein C-III sialylation proteoforms with plasma triglycerides. PLoS One 2015;10:e0144138.10.1371/journal.pone.0144138Search in Google Scholar PubMed PubMed Central

18. Koska J, Yassine H, Trenchevska O, Sinari S, Schwenke DC, Yen FT, et al. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. J Lipid Res 2016;57:894–905.10.1194/jlr.P064816Search in Google Scholar PubMed PubMed Central

19. Wopereis S, Grunewald S, Morava E, Penzien JM, Briones P, Garcia-Silva MT, et al. Apolipoprotein C-III isofocusing in the diagnosis of genetic defects in O-glycan biosynthesis. Clin Chem 2003;49:1839–45.10.1373/clinchem.2003.022541Search in Google Scholar PubMed

20. Wada Y, Kadoya M, Okamoto N. Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient. Glycobiology 2012;22:1140–4.10.1093/glycob/cws086Search in Google Scholar PubMed

21. Mauger JF, Couture P, Bergeron N, Lamarche B. Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism. J Lipid Res 2006;47:1212–8.10.1194/jlr.M500455-JLR200Search in Google Scholar PubMed

22. Kashyap ML, Hynd BA, Robinson K, Gartside PS. Abnormal preponderance of sialylated apolipoprotein CIII in triglyceride rich lipoproteins in type V hyperlipoproteinemia. Metabolism 1981;30:111–8.10.1016/0026-0495(81)90158-XSearch in Google Scholar

23. Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 2007;48:1190–203.10.1194/jlr.P600011-JLR200Search in Google Scholar PubMed

24. Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 2010;30:239–45.10.1161/ATVBAHA.109.197830Search in Google Scholar PubMed PubMed Central

25. Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol 2015;26:56–63.10.1097/MOL.0000000000000146Search in Google Scholar PubMed PubMed Central

26. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999;19:472–84.10.1161/01.ATV.19.3.472Search in Google Scholar

27. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189–97.10.1038/ng.75Search in Google Scholar PubMed PubMed Central

28. Bennett EP, Weghuis DO, Merkx G, van Kessel AG, Eiberg H, Clausen H. Genomic organization and chromosomal localization of three members of the UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferase family. Glycobiology 1998;8:547–55.10.1093/glycob/8.6.547Search in Google Scholar PubMed

29. Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, Herman DS, et al. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metab 2011;14:811–8.10.1016/j.cmet.2011.11.005Search in Google Scholar PubMed PubMed Central

30. Larsson M, Allan CM, Jung RS, Heizer PJ, Beigneux AP, Young SG, et al. Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL. J Lipid Res 2017;58:1893–902.10.1194/jlr.M078220Search in Google Scholar PubMed PubMed Central

31. Mysling S, Kristensen KK, Larsson M, Beigneux AP, Gardsvoll H, Fong LG, et al. The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain. Elife 2016;5:e12095.10.7554/eLife.12095Search in Google Scholar PubMed PubMed Central

32. Mysling S, Kristensen KK, Larsson M, Kovrov O, Bensadouen A, Jorgensen TJ, et al. The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding. Elife 2016;5:e20958.10.7554/eLife.20958Search in Google Scholar PubMed PubMed Central

33. Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci 2015;36:675–87.10.1016/j.tips.2015.07.001Search in Google Scholar PubMed

Supplementary Material:

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2017-1099).

Received: 2017-11-24
Accepted: 2018-03-09
Published Online: 2018-04-13
Published in Print: 2018-08-28

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Clinical Chemistry and Laboratory Medicine continues to shine brightly in the constellation of laboratory medicine
  4. The Theranos saga and the consequences
  5. Innovative approaches in diabetes diagnosis and monitoring: less invasive, less expensive… but less, equally or more efficient?
  6. Reviews
  7. Exploring the microbiota to better understand gastrointestinal cancers physiology
  8. Linking type 2 diabetes and gynecological cancer: an introductory overview
  9. Mini Reviews
  10. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
  11. Salivary biomarkers and cardiovascular disease: a systematic review
  12. Opinion Paper
  13. The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry
  14. General Clinical Chemistry and Laboratory Medicine
  15. Uncertainty evaluation in clinical chemistry, immunoassay, hematology and coagulation analytes using only external quality assessment data
  16. Measurement uncertainty and metrological traceability of whole blood cyclosporin A mass concentration results obtained by UHPLC-MS/MS
  17. Computer-assisted interventions in the clinical laboratory process improve the diagnosis and treatment of severe vitamin B12 deficiency
  18. Trueness, precision and stability of the LIAISON 1-84 parathyroid hormone (PTH) third-generation assay: comparison to existing intact PTH assays
  19. Fibroblast growth factor 23 and renal function among young and healthy individuals
  20. Optimizing charge state distribution is a prerequisite for accurate protein biomarker quantification with LC-MS/MS, as illustrated by hepcidin measurement
  21. Quantification of human complement C2 protein using an automated turbidimetric immunoassay
  22. EE score: an index for simple differentiation of homozygous hemoglobin E and hemoglobin E-β0-thalassemia
  23. Reference Values and Biological Variations
  24. Algorithm on age partitioning for estimation of reference intervals using clinical laboratory database exemplified with plasma creatinine
  25. A simple transformation independent method for outlier definition
  26. Cancer Diagnostics
  27. Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method
  28. Cardiovascular Diseases
  29. Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease
  30. Diabetes
  31. Analysis of protein glycation in human fingernail clippings with near-infrared (NIR) spectroscopy as an alternative technique for the diagnosis of diabetes mellitus
  32. Letter to the Editor
  33. Preanalytical errors before and after implementation of an automatic blood tube labeling system in two outpatient phlebotomy centers
  34. Hemolysis interference studies: freeze method should be used in the preparation of hemolyzed samples
  35. The curious case of postprandial glucose less than fasting glucose: little things that matter much
  36. Finding best practice in internal quality control procedures using external quality assurance performance
  37. Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I
  38. Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease
  39. Antigen excess detection by automated assays for free light chains
  40. Multiple myeloma and macro creatine kinase type 1: the first case report
  41. Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer
  42. Can we use a point-of-care blood gas analyzer to measure the lactate concentration in cerebrospinal fluid of patients with suspected meningitis?
  43. Unstable haemoglobin variant Hb Leiden is detected on Sysmex XN-Series analysers
  44. Congress Abstracts
  45. 59th National Congress of the Hungarian Society of Laboratory Medicine
https://doi.org/10.1515/cclm-2017-1099
Keywords for this article
apolipoprotein C-III; coronary artery disease; glycoforms; lipoprotein lipase; plasma lipids

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Clinical Chemistry and Laboratory Medicine continues to shine brightly in the constellation of laboratory medicine
  4. The Theranos saga and the consequences
  5. Innovative approaches in diabetes diagnosis and monitoring: less invasive, less expensive… but less, equally or more efficient?
  6. Reviews
  7. Exploring the microbiota to better understand gastrointestinal cancers physiology
  8. Linking type 2 diabetes and gynecological cancer: an introductory overview
  9. Mini Reviews
  10. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
  11. Salivary biomarkers and cardiovascular disease: a systematic review
  12. Opinion Paper
  13. The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry
  14. General Clinical Chemistry and Laboratory Medicine
  15. Uncertainty evaluation in clinical chemistry, immunoassay, hematology and coagulation analytes using only external quality assessment data
  16. Measurement uncertainty and metrological traceability of whole blood cyclosporin A mass concentration results obtained by UHPLC-MS/MS
  17. Computer-assisted interventions in the clinical laboratory process improve the diagnosis and treatment of severe vitamin B12 deficiency
  18. Trueness, precision and stability of the LIAISON 1-84 parathyroid hormone (PTH) third-generation assay: comparison to existing intact PTH assays
  19. Fibroblast growth factor 23 and renal function among young and healthy individuals
  20. Optimizing charge state distribution is a prerequisite for accurate protein biomarker quantification with LC-MS/MS, as illustrated by hepcidin measurement
  21. Quantification of human complement C2 protein using an automated turbidimetric immunoassay
  22. EE score: an index for simple differentiation of homozygous hemoglobin E and hemoglobin E-β0-thalassemia
  23. Reference Values and Biological Variations
  24. Algorithm on age partitioning for estimation of reference intervals using clinical laboratory database exemplified with plasma creatinine
  25. A simple transformation independent method for outlier definition
  26. Cancer Diagnostics
  27. Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method
  28. Cardiovascular Diseases
  29. Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease
  30. Diabetes
  31. Analysis of protein glycation in human fingernail clippings with near-infrared (NIR) spectroscopy as an alternative technique for the diagnosis of diabetes mellitus
  32. Letter to the Editor
  33. Preanalytical errors before and after implementation of an automatic blood tube labeling system in two outpatient phlebotomy centers
  34. Hemolysis interference studies: freeze method should be used in the preparation of hemolyzed samples
  35. The curious case of postprandial glucose less than fasting glucose: little things that matter much
  36. Finding best practice in internal quality control procedures using external quality assurance performance
  37. Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I
  38. Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease
  39. Antigen excess detection by automated assays for free light chains
  40. Multiple myeloma and macro creatine kinase type 1: the first case report
  41. Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer
  42. Can we use a point-of-care blood gas analyzer to measure the lactate concentration in cerebrospinal fluid of patients with suspected meningitis?
  43. Unstable haemoglobin variant Hb Leiden is detected on Sysmex XN-Series analysers
  44. Congress Abstracts
  45. 59th National Congress of the Hungarian Society of Laboratory Medicine
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 17.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2017-1099/html
Scroll to top button